• KOL
    • Atrial Fibrillation
    • Gregory Yoke Hong Lip
    • Gregory Yoke Hong Lip: Influence Statistics

      Gregory Yoke Hong Lip

      Gregory Yoke Hong Lip

      Show email address

      Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK | University of Liverpool and Liverpool ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Gregory Yoke Hong Lip:Expert Impact

      Concepts for whichGregory Yoke Hong Liphas direct influence:Atrial fibrillation,Heart failure,Patients atrial fibrillation,Stroke prevention,Ischemic stroke,Major bleeding,Oral anticoagulants,Stroke risk.

      Gregory Yoke Hong Lip:KOL impact

      Concepts related to the work of other authors for whichfor which Gregory Yoke Hong Lip has influence:Atrial fibrillation,Heart failure,Blood pressure,Myocardial infarction,Cardiovascular disease,Ischemic stroke,Catheter ablation.

      KOL Resume for Gregory Yoke Hong Lip

      Year
      2022

      Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK

      Department of Clinical Medicine, Aalborg, Denmark

      Liverpool Heart and Chest Hospital, Liverpool, United Kingdom of Great Britain & Northern Ireland

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Gregory Yoke Hong Lip is among the top experts in the world.
      Concept World rank
      apixaban endogenous fibrinolysis #1
      fibrillation european #1
      patients antithrombotic treatment #1
      warfarin ischaemic stroke #1
      oral anticoagulants noacs #1
      cha2 ds2 #1
      time therapeutic range #1
      stroke compared #1
      asian patients #1
      antagonist oral #1
      antagonists vkas #1
      factors bleeding #1
      renal dysfunction females #1
      discordance dabigatran dosage #1
      warfarin anticoagulants #1
      anticoagulation control warfarin #1
      scheduled cardioversion #1
      posología #1
      oac dapt #1
      platelet levels vegf #1
      spsel #1
      consensus document ehra #1
      hf disease controls #1
      plasma willebrand #1
      noacs higher risk #1
      orbit bleeding #1
      oac noac #1
      mpc pcdw #1
      fibrillation increased #1
      atria orbit #1
      warfarin patients #1
      risk scores patients #1
      noac trials #1
      patients c2hest score #1
      rivaroxaban treatment warfarin #1
      hasbled score patients #1
      dabigatran nvaf #1
      noacs aspirin therapy #1
      vwf sel #1
      hypertension relation #1
      plasma fibrinogen patients #1
      apixaban noacs #1
      mht female follow #1
      noacs edoxaban #1
      chf patients dm #1
      birmingham atrial #1
      healthy hearts project #1
      indices endothelial #1
      life 12 months #1
      bmegs #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Gregory Yoke Hong Lip

      KOL-Index: 24001

      North American and European guidelines on atrial fibrillation (AF) are conflicting regarding the classification of patients at low/intermediate risk of stroke. We aimed to investigate if the CHA2DS2-VASc score improved risk stratification of AF patients with a CHADS2 score of 0-1. Using individual-level-linkage of nationwide Danish registries 1997-2008, we identified patients discharged with AF having a CHADS2 score of 0-1 and not treated with vitamin K antagonist or heparin. In patients ...

      Known for Chads2 Score | Atrial Fibrillation | Risk Stratification | Cha2ds2 Vasc | Stroke Patients
      KOL-Index: 23856

      BACKGROUND: Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).

      OBJECTIVES: To compare the major bleeding risk among newly anticoagulated non-valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxaban in the United States.

      METHODS AND RESULTS: A retrospective cohort study was conducted to compare the major bleeding risk among newly anticoagulated NVAF patients initiating warfarin, ...

      Known for Major Bleeding | United States | Apixaban Warfarin | Dabigatran Rivaroxaban | Fibrillation Patients
      KOL-Index: 23090

      OBJECTIVE: To do an indirect comparison analysis of apixaban against dabigatran etexilate (2 doses) and rivaroxaban (1 dose), as well as of rivaroxaban against dabigatranetexilate (2 doses), for their relative efficacy and safety against each other, with particular focus on the secondary prevention population for stroke prevention in atrial fibrillation. A secondary objective was to do the same analysis in the primary prevention cohort.

      DESIGN: Indirect treatment comparisons of phase III ...

      Known for Secondary Prevention | Rivaroxaban Dabigatran | Atrial Fibrillation | Hazard Ratio | Differences Efficacy
      KOL-Index: 22232

      OBJECTIVES: This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative efficacy and safety against each other.

      BACKGROUND: Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinical trials of stroke prevention in atrial fibrillation (AF) are now available for the oral direct thrombin inhibitor, dabigatran etexilate, in 2 doses (150 mg twice daily [BID], 110 mg BID), ...

      Known for Rivaroxaban Dabigatran | Indirect Comparisons | Stroke Prevention | Atrial Fibrillation | New Oral
      KOL-Index: 21828

      OBJECTIVE: To determine whether chronic atrial fibrillation is associated with abnormalities in plasma fibrinogen, von Willebrand factor (vWF) (a marker of endothelial disturbance), or fibrin D- dimer (a measure of fibrin turnover); and if so, whether such levels are related to haemodynamic disturbance (enlarged left atrium, poor left ventricular function) or existing treatment with warfarin or aspirin. To investigate the effects of introducing warfarin in patients with atrial ...

      Known for Chronic Atrial Fibrillation | Warfarin Treatment | Plasma Fibrinogen | Median Difference | 95 Patients
      KOL-Index: 21663

      Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against ...

      Known for Stroke Prevention | Atrial Fibrillation | Dabigatran Rivaroxaban | Major Bleeding 95 | Efficacy Safety
      KOL-Index: 21383

      Importance: The risk of osteoporotic fracture with dabigatran use in patients with nonvalvular atrial fibrillation (NVAF) is unknown.

      Objective: To investigate the risk of osteoporotic fracture with dabigatran vs warfarin in patients with NVAF.

      Design, Setting, and Participants: Retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with NVAF from 2010 through 2014 and prescribed dabigatran or warfarin were ...

      Known for Osteoporotic Fracture | Warfarin Risk | Nonvalvular Atrial Fibrillation | Patients Nvaf | Dabigatran Databases
      KOL-Index: 21049

      OBJECTIVES: To evaluate the relative effectiveness and cost-effectiveness of a home-based programme of cardiac rehabilitation using the Heart Manual, with centre-based programmes. It also sought to explore the reasons for non-adherence to cardiac rehabilitation programmes.

      DESIGN: An individually randomised trial, with minimisation for age, gender, ethnicity, initial diagnosis and hospital of recruitment. Participants were followed up after 6, 12 and 24 months by questionnaire and ...

      Known for Cardiac Rehabilitation | Heart Manual | Patients Hospital Programme | Physical Activity | Patient Adherence
      KOL-Index: 20767

      In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited data on the comparative risks of major bleeding among newly anticoagulated NVAF patients who initiate warfarin, apixaban, dabigatran, or rivaroxaban, when used in 'real world' clinical practice. The study used the Truven MarketScan® Commercial & Medicare supplemental US claims database. NVAF patients ...

      Known for Major Bleeding | Apixaban Dabigatran | Rivaroxaban Warfarin | Fibrillation Patients | Lower Risk
      KOL-Index: 20702

      In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of ...

      Known for European Association | Acute Coronary | Atrial Fibrillation Patients | Heart Rhythm | Consensus Document
      KOL-Index: 20456

      IMPORTANCE: The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75 years, sex category [female]) is used clinically for stroke risk stratification in atrial fibrillation (AF). Its usefulness in a population of patients with heart failure (HF) is unclear.

      OBJECTIVE: To investigate ...

      Known for Ischemic Stroke | Vasc Score | Heart Failure | Death Patients | Atrial Fibrillation
      KOL-Index: 20372

      OBJECTIVES: Various bleeding risk prediction schemes, such as the Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized Ratio, Elderly, Drugs/alcohol (HAS-BLED), Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA), and Outcomes Registry for Better Informed Treatment (ORBIT) scores, have been proposed in patients with atrial fibrillation. We compared the relative predictive values of these bleeding risk scores ...

      Known for Risk Scores | Orbit Bleeding | Atrial Fibrillation | Therapeutic Range | Hasbled Score
      KOL-Index: 20177

      OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.

      BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...

      Known for Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk
      KOL-Index: 20108

      OBJECTIVES: The aim of this study was to assess the efficacy and safety in an "everyday clinical practice" population of anticoagulant-naïve patients with atrial fibrillation (AF) treated with dabigatran etexilate after its post-approval availability in Denmark, compared with warfarin.

      BACKGROUND: Concerns have been raised about an excess of bleeding events or myocardial infarction (MI) among patients treated with the new oral direct thrombin inhibitor, dabigatran etexilate.

      METHODS: ...

      Known for Warfarin Dabigatran | Atrial Fibrillation | 110 Bid | Intracranial Bleeding | Efficacy Safety

      Key People For Atrial Fibrillation

      Top KOLs in the world
      #1
      Gregory Yoke Hong Lip
      atrial fibrillation heart failure stroke prevention
      #2
      John Camm MD John Camm
      atrial fibrillation myocardial infarction heart rate
      #3
      Emelia J Benjamin
      atrial fibrillation framingham heart study heart failure
      #4
      Harry J G M C Crijns
      atrial fibrillation heart failure sinus rhythm
      #5
      Isabelle C Van Gelder
      atrial fibrillation heart failure rate control
      #6
      Stefan Hans Hohnloser
      atrial fibrillation myocardial infarction sinus rhythm

      Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK | University of Liverpool and Liverpool Heart and Chest, Liverpool, UK | University of Liverpool | Liverpool Centre fo

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.